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Abstract. 
Immune checkpoint inhibitors (ICIs) targeting Cytotoxic T-Lymphocyte-Associated protein 4 
(CTLA-4) or Programmed cell Death protein 1 (PD-1) receptors have demonstrated remarkable 
efficacy in subsets of patients with malignant disease. This emerging treatment modality holds 
great promise for future cancer treatment and has engaged pharmaceutical research interests 
in tumour immunology. While ICIs can induce rapid and durable responses in some patients, 
identifying predictive factors for effective clinical responses has proven challenging. This review 
summarises the mechanisms of action of ICIs and outlines important pre-clinical work that 
contributed to their development. We explore clinical data that has led to disease-specific drug 
licensing, and highlight key clinical trials that have revealed ICI efficacy across a range of 
malignancies. We describe how ICIs have been used as part of combination therapies, and 
explore their future prospects in this area. We conclude by discussing the incorporation of these 
new immunotherapeutics into precision approaches to cancer therapy.     
 
Introduction. 
There are extensive interactions between tumour cells and the components of the immune 
system. The process of immune surveillance ensures that aberrant cells with tumorigenic 
potential can undergo immune destruction before they develop into cancers, and from the very 
earliest stages of tumour development the tumour microenvironment (TME) contains often-
substantial populations of leukocytes, including various subsets of T-cells [1, 2]. Effector T-cell 
responses against tumour antigens are induced early during tumour development. Local 
dendritic cells (DCs) can acquire and process tumour proteins from lysed tumour cells, including 
mutated versions of normal proteins, and present peptides from these proteins to naïve T-cells 
in secondary lymphoid organs. This has the potential of generating potent tumour-specific 
effector T cells that could home to the tumour and facilitate selective tumour cell killing. 
However, tumours evolve diverse mechanisms of immune evasion and immunosuppression to 
prevent or restrain anti-tumour T-cell responses [3, 4]. This includes changing their antigen 
profile (to make them unrecognisable to effector T-cells [5, 6]), blocking T-cell recruitment [7, 8], 
and exploiting immunosuppressive leukocytes, such as regulatory T-cells (Tregs) and tumour-
associated macrophages [9-11]. In addition, cancer cells and/or the tumour microenvironment 
(TME) can produce molecules that actively inhibit any tumour-specific T-cells that do manage to 
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enter the tumour [12-14]. All these processes are potential targets for therapeutic interventions 
that aim to induce, re-instate or enhance anti-tumour T cell responses. There have been several 
exciting recent successes with cancer immunotherapies: principal among these are antibodies 
targeting the ‘immune checkpoint’ proteins CTLA-4 or PD-1. 
Enhancing anti-tumour T cell responses with anti-CTLA-4 antibodies. 
Full activation of naïve T-cells results in clonal expansion and the development of effector 
functions. This requires positive signals from several membrane receptors. ‘Signal one’ comes 
from the T cell receptor (TCR) after it engages cognate antigen displayed on target cell MHC, but 
secondary positive signals (co-stimulation) are also essential, while further signals through 
cytokine receptors shape effector T-cell phenotype [15-18]. Co-stimulatory signals are 
principally delivered through CD28 receptors after they bind CD80 and CD86 (also known as 
B7.1 and B7.2, respectively), which are abundantly expressed on mature DCs. CTLA-4 also binds 
to CD80/86 with higher affinity than CD28 but it negatively regulates co-stimulation [19, 20]. 
CTLA-4 is transiently induced on activated T-cells, peaking 2-3 days after initial activation [19], 
and is strongly expressed by Treg: naturally occurring Treg (nTreg) are the major cell type 
constitutively expressing this molecule [9]. The receptor CTLA-4 is reported to transduce 
negative intracellular signals [21, 22] and enhance T cell motility [23, 24], but perhaps more 
significant is its ability to outcompete CD28 molecules for CD80/86 binding [19, 24, 25]; displace 
CD28 to distal regions of the immunological synapse [26, 27]; and strip CD80/86 from the 
surface of dendritic cells [28, 29]. These immunosuppressive activities prevent or restrain T-cell 
activation, and ensure that auto-reactive T-cells, or those that bind weakly to antigen, fail to 
become activated and instead enter a state of unresponsiveness (anergy).  
The immunosuppressive properties of CTLA-4 are evident in Ctla4-deficient mice, which develop 
fatal lymphoproliferative disease and multi-organ failure due to unopposed T-cell activation and 
loss of immunological tolerance [30, 31]. These phenotypes are rescued by blocking or deleting 
CD80/86 or CD28. Moreover, germline heterozygous mutations in CTLA4 in humans are linked 
to severe immune dysregulation [32, 33], and a CTLA4 variant is associated with early onset 
Crohn’s disease and autoimmunity [34]. Individuals with CTLA4 mutations have defective Treg 
function, hyperactivated effector T cells, and reduced numbers of circulating B cells [32, 33]. 
It is well established that anti-CTLA-4 monoclonal antibodies can block the immunosuppressive 
properties of CTLA-4 and enhance anti-tumour T-cell responses in animal models [35, 36]. 
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Blockade induces a reduction in Tregs and an increase in effector T-cells within the TME, and 
simultaneous blockade of CTLA-4 on these cells can synergise to enhance anti-tumour responses 
in animal models [37-43]. Anti-CTLA-4 antibodies can also bind Fcγ receptors (FcγRs) to mediate 
antibody-dependent cell-mediated cytotoxicity against CTLA-4+ Tregs, leading to their selective 
depletion [40-43]. This is largely dependent on the presence of atypical, FcγR-expressing 
macrophages in the tumour [40-43] and this mechanism of intra-tumoural Treg depletion has 
been identified in humans treated with ipilimumab [44]. 
The functional effects of anti-CTLA-4 antibodies on anti-tumour responses in a patient depend 
on the characteristics of the patient’s tumour, the underlying TME, and the nature of any 
previous or concurrent therapies. Predicting responses is challenging and, given the profound 
immunological consequences of Ctla4 deletion, or genetic variation in CTLA4, the potential side 
effects of administering anti-CTLA-4 antibodies may be significant. However the preclinical 
research and clinical trial data from CTLA4 blockade has provided a proof-of-principle and laid 
the groundwork for further targeted disruption of other immune checkpoints such as the PD-1 / 
PL-L1 axis. 
Dismantling tumour defence by inhibiting PD-1 activity. 
PD-1 is a surface receptor for the cognate ligands PD-L1 and PD-L2. It is expressed 
predominantly by activated T cells, but is also found on other leukocyte subsets, including 
activated B-cells, DCs, monocytes and NK cells [45-47]. PD-L1 can be found on activated T- and 
B-cells, DCs, macrophages and many tissue cells [47-50], while PD-L2 appears limited to DCs and 
macrophages and some stromal cells [47]. On effector T-cells, PD-1 ligation causes 
dephosphorylation of key signalling molecules that lie downstream of the TCR, thereby 
dampening TCR-mediated T-cell activation [51, 52]. It has also recently been identified that PD-1 
/ PD-L1 interactions trigger dephosphorylation of CD28 preferentially over the TCR, and is the 
primary mechanism of T cell suppression [53]. PD-1 also enhances T-cell motility to limit T-
cell/DC interactions [54]. PD-L1 has also been reported to bind to CD80 and might, like CTLA-4, 
compete with CD28 [55]. Deletion of Pd-1 leads to autoimmune disease [56, 57], but this 
develops later in life than the more severe, early onset disease in Ctla4-/- mice [30, 31]. 
Expression of PD-L2 in lymphoid organs is thought to help maintain tolerance [51], while PD-L1, 
which is upregulated in response to interferons, particularly IFN-γ, protects tissues from 
excessive immune cell activity [48, 49]. This occurs during chronic viral infection when persistent 
viral antigen exposure causes T-cell exhaustion, a form of anergy [58, 59]. In this context, 
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blockade of PD-L1 by administration of anti-PD-L1 antibodies causes a resurgence of effector T-
cell activity [60], predominantly through reactivation of the CD28 signalling pathway [61]. Thus, 
the physiological functions of the PD-1 pathway are to maintain T-cell tolerance and suppress 
effector T-cell responses in peripheral tissues. 
Cancers can exploit the PD-1 pathway, upregulating PD-1 ligands to suppress T-cell-mediated 
cytolysis. Up-regulated PD-1 expression by tumour-infiltrating lymphocytes is associated with 
poor outcomes in many human cancers and correlates with an exhausted T-cell phenotype that 
impedes tumour immunity [62-67]. Early in vivo experiments demonstrated that myeloma cells 
were more effectively targeted when Pd-1 was absent, and that anti-PD-L1 antibodies could 
suppress myeloma in wild-type mice [68]. In other mouse models, transplantation of Pd-1-/- T 
cells [69] or administration of anti-PD-L1 antibodies [68, 69] induced regression of established 
tumours. PD-L1 expression by infiltrating myeloid cells has also been shown to impair anti-
tumour T-cell immunity [72, 73], but interestingly this may be due in part to the induction and 
regulation of peripherally induced Treg subsets (iTreg) by the PD-L1-expressing myeloid cells 
[74]. Disruption of this process may represent an additional mechanism underpinning the 
enhanced anti-tumour immunity that can be induced by PD-1 blockade.  
Translating efficacy from bench to bedside. 
CTLA-4 and PD-1 provide critical but discrete mechanisms of physiological immunoregulation. A 
wealth of experimental data shows that antibodies blocking these checkpoints can enhance 
anti-tumour immune responses in animal models. Despite some concerns over potential 
toxicities, this drove the development of humanised monoclonal antibodies targeting these 
molecules. These novel immunotherapies are referred to as ‘immune checkpoint inhibitors’ 
(ICIs). These have now been licensed in a number of different tumour types (Figure 1), and are 
discussed briefly here. 
 
Anti-CTLA-4: licensing ipilimumab for metastatic melanoma. 
Ipilimumab (Bristol Myers Squibb), an anti-CTLA-4 antibody, was licensed for malignant 
melanoma in 2011 [73]. This followed a landmark phase III clinical trial involving around 600 
patients with previously treated malignant melanoma [76] (Table 1). There were three 
treatment arms: ipilimumab plus gp100 vaccine, ipilimumab alone, or gp100 vaccine alone. The 
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gp100 vaccine targets a protein abundantly expressed by melanomas [77, 78]. The treatments 
containing ipilimumab conferred greatest median overall survival (OS): 10.0 months 
(ipilimumab/gp100) and 10.1 months (ipilimumab monotherapy) versus 6.4 months (gp100 
vaccine alone). Severe immune-related adverse effects (IAEs) were reported in 10-15% of 
patients receiving ipilimumab, and were of longer duration in the ipilimumab/gp100 cohort [76]. 
Established protocols for managing immune-mediated toxicities were adopted from previous 
trials [79-81]. Subsequent analysis of data from 1,861 metastatic melanoma patients in 12 
individual clinical trials of ipilimumab showed that OS at 3 years was 20% for previously treated 
patients and 26% for treatment-naive patients [82]. The survival curve plateaued at around 3 
years, with evidence of long-term progression-free survival of up to 10 years in some patients.  
PD-1 blockade moves into the clinic.   
The safety and efficacy of pembrolizumab (Merck), a monoclonal antibody targeting PD-1, was 
demonstrated in patients with ipilimumab-refractory malignant melanoma. In an expansion 
cohort of a phase I trial, 173 patients were treated every 3 weeks with pembrolizumab [83]. 
Equivalent efficacy, as determined by overall response rates (ORR) [84], was observed at both 
dosing regimens (ORR=26%). Pembrolizumab was well tolerated: only 12% of patients 
developed drug-related grade 3 / 4 toxicities. Given the promising clinical responses, good 
safety profiles and absence of other effective therapies, pembrolizumab was licensed for 
ipilimumab-resistant advanced melanoma in 2014 [85].  
In 2015, Robert and colleagues demonstrated significant improvements in progression-free 
survival, OS, response rates, and treatment related adverse events of pembrolizumab 
monotherapy compared with ipilimumab in advanced melanoma [86] (Table 1). A total of 834 
patients were randomised to either pembrolizumab every 2 weeks, pembrolizumab every 3 
weeks, or four cycles of ipilimumab every 3 weeks. The 12- and 24-month OS was significantly 
greater in the pembrolizumab groups, and progression-free survival at 6 months was 47.3%, 
46.4% and 26.5%, respectively, with more durable responses seen in the pembrolizumab groups 
at 7.9 months [87]. Lower rates of significant immune-mediated toxicities were also seen in the 
pembrolizumab groups. 
A phase I clinical trial of another anti-PD-1 monoclonal antibody, nivolumab (Bristol Myers 
Squibb), was conducted in 296 patients with melanoma, non-small-cell lung cancer (NSCLC), 
renal cell carcinoma (RCC) or other selected treatment-refractory malignancies [88]. Melanoma 
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patients were treated every 2 weeks with increasing doses of 0.1-10mg/kg and showed overall 
objective response rates of 28%, with the highest response rate (41%) at a dose of 3mg/kg. 
Responses were durable in many responders. Grade 3/4 treatment related adverse events 
occurred in 14% of patients, with IAEs in 6%. Longer-term follow up of melanoma patients 
showed 1- and 2-year survival rates of 62% and 43% respectively, with an OS of 16.8 months 
[89]. Long-term safety evaluation was comparable to the original analysis, with 22% 
experiencing grade 3/4 treatment related adverse events and 5% having grade 3/4 IAEs. 
Toxicities were not cumulative and almost exclusively occurred in the first 6 months of therapy. 
In an open-label, randomized, phase III study involving patients with ipilimumab-refractory 
melanoma, nivolumab was associated with a higher ORR than chemotherapy (32% versus 11%) 
[90]. Subsequently, nivolumab was compared with dacarbazine in patients with previously 
untreated metastatic melanoma without BRAF mutation [91]. Nivolumab gave superior 1-year 
survival (72% versus 42%), progression-free survival (5.1 versus 2.2 months), and ORRs (40% 
versus 13.9%). The survival benefit with nivolumab was observed across pre-specified subgroups, 
including those defined by PD-L1 status. Grade 3/4 drug-related adverse events occurred in 11.7% 
of nivolumab-treated patients and 17.6% of those receiving dacarbazine.   
Combination regimens of ICIs in patients with advanced melanoma. 
The distinct mechanisms of actions of anti-PD-1 and anti-CTLA-4 infer that their co-
administration could have enhanced efficacy (Figure 2). The first phase I study combining two 
ICIs, nivolumab and ipilimumab, was undertaken in patients with malignant melanoma and used 
an initial dose-escalation trial design to identify safe doses of these drugs when used in 
combination regimens [92]. 1mg/kg nivolumab and 3mg/kg ipilimumab were the maximum 
doses associated with acceptable levels of adverse events. This regimen yielded objective 
responses in 21/52 patients (40%). Durable responses, ranging from 6.1 to 72.1 weeks, were 
ongoing in 19 patients at the time of publication. Impressively, 16 patients had tumour 
reduction ≥80% at 12 weeks, including 5 with a complete response, although treatment-related 
grade 3/4 adverse events were reported in 53% of patients. Updated OS data was 82% and 75% 
for 1- and 2-year survival, respectively (Table 1) [93]. Thus, this preliminary trial data indicated 
that simultaneous targeting of PD-1 and CTLA-4 could be tolerated and result in durable 
responses.  
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The Checkmate 069 trial compared nivolumab plus ipilimumab, with ipilimumab monotherapy 
in patients with untreated malignant melanoma (Table 1). Greater objective responses were 
seen with combination therapy (61% versus 11% with ipilimumab alone), with complete 
responses in 22% of patients on combination therapy but none with ipilimumab alone [94]. 1- 
and 2-year OS was 73.4% and 63.8%, respectively, in the combination cohort, compared with 
64.8% and 53.6% with ipilimumab alone [95]. Importantly, 2-year survival was not significantly 
affected by BRAF mutation or tumour PD-L1 expression status at diagnosis. A large subsequent 
phase III trial (Checkmate 067) compared nivolumab alone, ipilimumab alone, and nivolumab 
plus ipilimumab: median progression-free survival was 6.9 months, 2.9 months and 11.5 months, 
respectively [96]. Notably, in patients with PD-L1-negative tumours, progression-free survival 
was greater with combination therapy than either monotherapy. Furthermore, with a minimum 
follow-up of 36 months, the median overall survival has not been reached in the combination 
regimen arm and was 37.6 months in the nivolumab arm of the study compared with 19.9 
months with ipilimumab monotherapy (HR = 0.55, P<0.001 for combination versus ipilimumab; 
HR= 0.65, P<0.001 for nivolumab versus ipilimumab). The overall survival at 3 years was 58%, 52% 
and 34% for the combination regimen, nivolumab, and ipilimumab monotherapy respectively. 
However, treatment-related grade 3 / 4 toxicities occurred in 59%, 21% and 28% of patients 
treated with the combination regimen, nivolumab, and ipilimumab respectively [97].  
A phase II trial (Checkmate 064) has also revealed intriguing results of switching between 
nivolumab and ipilimumab [98]. Melanoma patients underwent induction with either nivolumab 
(3mg/kg every 2 weeks; six doses) and then ipilimumab (3mg/kg every 3 weeks; four doses), or 
the reverse sequence. This was followed by maintenance therapy with nivolumab (3mg/kg every 
2 weeks) in both cohorts. Greater efficacy was observed in the nivolumab followed by 
ipilimumab cohort, with significantly greater 1-year OS than the reverse sequence (Table 1). As 
expected from previous combination trials, the frequency of IAEs was relatively high (43-50%), 
although this was not affected by the order of drug administration. 
Collectively, these trials have allowed ICIs, either alone or in combination, to herald in a new era 
of immunotherapy for the treatment of malignant melanoma. Impressive durable responses 
have led to unprecedented improvements for some patients with metastatic disease. 
Administering ICIs in combination with other therapeutics will no doubt further expand their use 
in cancer patients. 
New therapeutic approaches for non-small-cell lung cancer. 
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Anti-CTLA-4 therapy has been trialled in patients with NSCLC but promising outcomes akin to 
those seen in patients with melanoma have not been forthcoming. One initial trial used 
tremelimumab, an anti-CTLA-4 antibody, but it showed minimal efficacy and a significant side 
effect burden [99], and, when used in combination with chemotherapy, anti-CTLA-4 antibodies 
have consistently demonstrated only modest improvements in responses in NSCLC patients [100, 
101]. However, antibodies targeting the PD-1/PD-L1 axis have shown greater efficacy and 
marked reductions in side effects so have largely replaced anti-CTLA-4 antibodies as the ICI of 
choice in NSCLC.   
In 2015, nivolumab received FDA approval for use in patients with advanced squamous-cell 
NSCLC who progressed during or after, platinum chemotherapy (Table 2) [85]. This followed a 
phase III trial (CheckMate-017) of nivolumab compared with docetaxel chemotherapy in 
patients with progressive disease following first-line chemotherapy [102]. Median OS was 9.2 
months in the nivolumab cohort, compared with 6.0 months in those receiving docetaxel. At 12 
months, OS was 42% with nivolumab, and 24% with docetaxel. Pre-treatment tumour PD-L1 
expression was not predictive of efficacy. A similar phase III trial (CheckMate-057) demonstrated 
considerable improvements in survival for patients with advanced non-squamous NSCLC treated 
with nivolumab compared to those receiving docetaxel [103]. OS at 12 and 18 months was 
higher for patients on nivolumab compared with those on docetaxel. An additional phase II trial 
(CheckMate-063) supports the survival benefit of nivolumab, reporting a 1-year OS of 40.8% 
[104]. Similarly, compared with docetaxel, pembrolizumab showed greater efficacy than 
docetaxel in advanced NSCLC in a phase II/III trial (KEYNOTE-010) [105, 106]. Patients with ≥1% 
PD-L1 expression on the tumour received 2mg/kg pembrolizumab, 10mg/kg pembrolizumab, or 
docetaxel, resulting in median OS of 10.4, 12.7 or 8.5 months, respectively. Greater efficacy was 
seen in patients with high tumour PD-L1 expression. These results echo findings from a similar 
phase I study (KEYNOTE-001) investigating pembrolizumab in NSCLC [107], while a phase III trial 
(KEYNOTE-024) demonstrated survival benefits, durable responses, increased response rates 
and reduced treatment-related adverse events with pembrolizumab compared with platinum-
based chemotherapy in previously untreated patients with ≥50% tumoural PD-L1 expression 
[108]. This has led to pembrolizumab being licensed for treatment of naïve metastatic NSCLC 
with ≥50% PD-L1 expression [83]. In contrast, nivolumab did not improve progression-free or 
overall survival compared with chemotherapy in patients (n=423) with previously untreated 
stage IV or recurrent NSCLC and with a PD-1 expression of 5% or more [109]. This suggests that 
robust predictive markers are required to optimally select patients for anti-PD-1 therapy, and 
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that the sequence of administration with other standard therapies may also be relevant for 
optimal treatment strategies.  
In the phase II POPLAR trial, atezolizumab (Genentech), an antibody targeting the PD-L1 rather 
than PD-1, showed improved OS for NSCLC patients who had progressed following platinum 
chemotherapy [110]. This study included prospective evaluation of tumour PD-L1 expression, 
and used immune gene expression to define and quantify effector T-cell activity within the TME. 
It was clear that efficacy was closely related to both PD-L1 expression and effector T-cell 
abundance in the tumour. Future studies should consider incorporating this pre-treatment 
analysis of the presence of active tumour-infiltrating effector T-cells that may be a predictive 
marker of ICI efficacy. The clinical outcomes of POPLAR were reiterated in OAK, a phase III 
clinical trial demonstrating improved median OS with atezolizumab versus docetaxel (13.8 
versus 9.6 months) in NSCLC patients progressing on platinum chemotherapy, although 
improvement in OS was seen regardless of tumour PD-L1 expression [111, 112]. As a result of 
these trials, in 2016 the FDA approved atezolizumab for the treatment of metastatic NSCLC that 
has progressed on platinum chemotherapy [85].  
Significantly, PD-L1/PD-1 inhibitors not only improve OS but they are also associated with fewer 
treatment-related adverse events (≥ grade 3) than chemotherapy [102, 103, 105, 108-111]. 
Moreover, they may have broad usage: although strongest responses were seen in patients with 
high tumour PD-L1 expression, they also showed similar, if not greater, efficacy than 
chemotherapy in patients with very low tumour PD-L1 expression [102-107, 110, 111]. It has not 
yet been possible to accurately stratify patient responses based on PD-L1 expression, although 
this typically involves the analysis of a single pre-treatment tumour biopsy, sometimes taken 
long before starting checkpoint blockade therapy. In the Checkmate-063 trial, for example, 
there was a median of 1.3 years between biopsy and commencing nivolumab [104]. Thus, more 
detailed studies are required to explore the prognostic value of tumour PD-L1 expression, and 
ideally analysis of effector T-cell abundance and phenotype should also be included.  
ICIs offer new hope for treating NSCLC, which historically has poor survival outcomes in patients 
with metastatic disease, and they have become standard second-line therapies in NSCLC 
patients. They are also being used as first-line treatments, particularly for patients with PD-L1-
expressing tumours, although optimal ICI treatment strategies, with or without chemotherapy, 
still need to be more precisely defined in this context [113]. Trials using a combination of anti-
CTLA4 and anti-PD-L1 antibodies have begun in NSCLC patients, with two phase I studies 
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demonstrating safety profiles comparable to those seen in melanoma patients (Table 2) [114, 
115]. The results of on-going phase II/III trials are eagerly anticipated [116-118]. Other studies 
have focused on including ICIs into treatment strategies either in combination or sequentially 
after other existing therapies in NSCLC. For example, patients (n=713) with locally advanced 
unresectable NSCLC were randomly assigned (2:1) to receive consolidation therapy with either 
the anti-PDL-1 antibody durvalumab, or placebo every 2 weeks for up to 12 months after 
definitive chemoradiotherapy (chemotherapy with concurrent radiotherapy). Patients treated 
with durvalumab had a significantly improved progression-free survival (16.8 months versus 5.6 
months; HR = 0.52, P<0.001) and objective response rates 28.4% versus 16%; P<0.001) [119].  
ICIs show efficacy in other cancers. 
ICIs have been, or are being, investigated in clinical trials across a broad range of other cancers 
in the hope that responses seen in patients with melanoma or NSCLC can be reproduced in 
patients with other tumour types. 
PD-L1 expression has long been known to be associated with tumour aggressiveness and poorer 
outcomes in patients with Renal Cell Carcinoma (RCC) [120, 121]. Nivolumab demonstrated 
efficacy in a phase II trial of 168 patients with metastatic RCC [122]. They received 0.2, 2 or 
10mg/kg of nivolumab: median OS was 18.2, 25.5 or 24.7 months, respectively. In a subsequent 
phase III study, patients that had previously received anti-angiogenic therapy had a median OS 
of 25.0 months on nivolumab compared with 19.6 months on everolimus (an mTOR inhibitor 
recommended after failed anti-angiogenic therapy) [123]. Nivolumab was subsequently 
approved for use in patients with advanced RCC after failing anti-angiogenic therapy [85]. 
Interestingly, high tumour PD-L1 expression was not associated with improved responses to 
therapy in this study: median OS in patients with PD-L1 expression ≥1% was 21.6 and 18.8 
months (nivolumab and everolimus, respectively), but 27.4 versus 21.2 months in patients with 
≤1% tumour PD-L1 expression. This emphasises the need to carefully consider the suitability of 
using PD-L1 expression alone to predict responses. 
Following two clinical trials [124, 125], atezolizumab, and more recently nivolumab, have been 
granted FDA approval for bladder cancer patients with disease progression within 12 months of 
treatment with platinum-containing chemotherapy [85]. The phase II trial using atezolizumab 
improved objective response rates compared with a historical control [124]. Approximately 15% 
of patients responded, and in this case, PD-L1 expression on tumour-associated immune cells 
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correlated with objective responses. Ongoing responses in 84% of responders demonstrate 
excellent treatment durability, and for a small fraction (5%) a complete response was observed. 
This trial attempted to define features of the TME associated with responses. In addition to PD-
L1 expression, it determined CD8+ T-cell infiltration, mutational load, and molecular subtype. 
Several ‘immune cell’ genes were associated with complete and partial responses to 
atezolizumab, including the IFN-γ-inducible genes CXCL9 and CXCL10, which encode chemokines 
that direct leukocyte and CD8+ T-cell homing. Mutational load was also significantly higher in 
responders than non-responders (12.4 versus 6.4 mutations per Mb). High mutational load has 
also been correlated with responses to anti-CTLA-4 in malignant melanoma [126], and may 
predict better survival in melanoma patients treated with anti-PD1 therapy [127]. This is most 
likely because increased mutation will increase the generation of neoantigens recognizable by T-
cells. Thus, in addition to characterizing PD-L1 expression and the immune cell infiltrate, efforts 
to predict ICI responses should take into account the mutational landscape of the tumour.  
Tumours with mismatch-repair (MMR) defects contain a large number of somatic mutations so 
may be particularly sensitive to ICIs. Indeed, in a recent phase II trial pembrolizumab was 
administered every two weeks to patients with MMR–deficient colorectal cancers (n=11), 
MMR–proficient colorectal cancers (n=21), or MMR–deficient cancers that were not colorectal 
(n=9) [128]. The objective response rate and progression-free survival rate at 20 weeks were 40% 
and 78% for MMR–deficient colorectal cancers; 71% and 67% for non-colorectal MMR–deficient 
cancers; and 0% and 11% for MMR–proficient colorectal cancers. This apparent sensitivity of 
MMR–deficient tumours supports the rationale of combining DNA repair inhibitors with ICIs in 
clinical trials, and a Phase I/II study combining the poly ADP Ribose Polymerase (PARP) inhibitor, 
olaparib, with durvalumab in patients with selected advanced malignancies is ongoing [129]. 
PD-1 blockade has shown positive outcomes in classical Hodgkin’s lymphoma. Nivolumab and 
pembrolizumab are now FDA-approved for treatment of patients who have relapsed after other 
therapies. Two clinical trials have reported ORRs of 65% and 87%, with complete response rates 
in 16% and 17% of patients [130, 131]. Nivolumab and pembrolizumab are also approved for use 
in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) 
whose disease has progressed after administration of platinum-based therapeutics [85]. 
Pembrolizumab treatment gave a clinically significant ORR, and durable responses were evident 
in some patients [132], while nivolumab improved overall survival compared to standard single-
agent therapy (methotrexate, docetaxel or cetuximab) [133]. However, in a phase III study of 
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pembrolizumab versus standard of care in patients with recurrent or metastatic SCCHN, 
pembrolizumab yielded a 19% reduction in the risk of death compared with standard of care, 
but this did not meet the pre-specified efficacy boundary, although it is possible that 
subsequent immunotherapy use in the standard of care arm may have confounded the overall 
survival analysis [134]. Nonetheless, greater differences in overall survival, progression-free 
survival, and objective response rates were seen in patients with PD-1-expressing tumours [134].  
Based on a phase II clinical trial involving 88 patients, avelumab (Merck – Pfizer), a PD-L1 
blocking antibody, received FDA approval for use in patients with metastatic Merkel cell 
carcinoma [85, 135]. This is the first ever drug approved for this rare skin cancer, in which 
Merkel cell polyomavirus infection is a major aetiological factor [136]. Nearly a third of patients 
showed objective responses, with eight complete responses reported: five grade 3 treatment-
related adverse events were noted [135]. Pembrolizumab has also been trialled on 26 patients 
with this disease, with an ORR of 56% being reported, including four complete responses [137].   
In a large phase III trial involving 1,132 patients with extensive late-stage small-cell lung cancer 
(SCLC), ipilimumab with chemotherapy versus placebo with chemotherapy demonstrated no 
significant difference in OS [138]. A previous phase I/II trial had also given disappointing results 
in SCLC, with no survival advantage for patients receiving ipilimumab [139]. However, nivolumab, 
either alone or in combination with ipilimumab, showed anti-tumour activity with durable 
responses and manageable safety profiles in previously treated patients with SCLC [140]. 
Patients were administered nivolumab (3mg/kg); nivolumab (1mg/kg) plus ipilimumab (3mg/kg); 
or nivolumab (3mg/kg) plus ipilimumab (1mg/kg). Objective responses were seen in 10%, 23% 
and 19% patients, respectively. Pembrolizumab is currently under investigation in patients with 
PD-L1+ (≥1% expression) SCLC, who have progressed during or after platinum-based 
chemotherapy [141]. Initial results indicate good tolerability and, while the data are preliminary, 
the initial report shows that 25% of SCLC patients developed a partial response.  
A phase III trial compared ipilimumab against placebo, following radiation, in patients with 
metastatic castration-resistant prostate cancer that progressed on docetaxel chemotherapy 
[142]. They reported no significant improvement in OS: median OS was 11.2 months for 
ipilimumab and 10.0 months for placebo. However, subgroup analysis revealed improved OS 
outcomes for patients with better prognostic factors. This is perhaps unsurprising, as it is now 
established that immunotherapies often take longer to show measurable efficacy [143].  Final 
results from a completed Phase III trial comparing placebo with ipilimumab in minimally 
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symptomatic, previously untreated patients with metastatic castration-resistant prostate cancer 
should reveal whether there is a role for ICIs in this malignancy [144]. Finally, promising 
responses have also been observed with anti-PD-1 antibodiy treatment in patients with 
refractory gastric cancer [145, 146] or hepatocellular carcinoma [147]: results of randomized 
trials are eagerly awaited. 
Thus, in addition to melanoma and NSCLC, ICI monotherapies, particularly those targeting the 
PD-1 pathway, are yielding positive outcomes in a range of metastatic cancers. Toxicities are 
evident and need to be managed, and the long-term health implications of ICI monotherapy 
have yet to be determined. This might be significant, given the improvements in patient survival 
seen with ICIs, though the issue of resistance to ICIs raises the challenge of how to treat cancers 
which fail multiple therapies.  
Future prospects for ICIs in combination therapies. 
Clinical trial data have justifiably generated considerable excitement about the effectiveness of 
ICIs. In many cases, responses are durable, perhaps even curative, possibly because they release 
systemic personalized memory T-cell responses against multiple patient-specific tumour 
antigens. However, only subsets of patients respond to ICI monotherapy. Combining ICIs can 
improve outcomes, and further ICI combination trials, with careful side effect monitoring, are 
certainly merited. There are also a large number of ongoing clinical trials exploring ICIs in 
combination with other treatment modalities, such as radiotherapy, chemotherapy, or 
molecular targeted therapies [148]. The administration of ICIs after radiotherapy attempts to 
augment the ‘abscopal effect’, where localized radiation-induced tumour cell death can deliver 
anti-tumour immune responses against distant tumour deposits (Figure 1) [149-154]. ICIs even 
show activity against tumours classically viewed as poorly immunogenic, such as pancreatic 
adenocarcinoma and glioblastoma, with efforts aimed at administering ICIs while either 
modifying the TME, up-regulating neoantigen abundance [155] or, in glioblastoma, potentiating 
immune responses using adenovirus [156]. Modulating the chemokine composition of the TME 
[157], or blocking chemokine receptors [158], can also enhance ICI efficacy in animal models, 
and these approaches may translate to humans. Preliminary data in animal tumour models has 
shown that depletion of Tregs via modified anti-CD25 antibody plus anti-PD-1 antibody can 
induce complete regression of established tumours [159]. In short, combination therapies have 
the potential to further improve the activity and scope of ICIs, leading to the induction of 
durable effector T-cell responses in more patients, and across a greater range of malignancies.  
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Integrating ICIs into precision oncology.  
The future of oncology will undoubtedly involve a precision approach to patient care, with 
treatment tailored to an individual’s disease to maximise efficacy and ameliorate side effects as 
far as possible. Numerous factors determine a patient’s response to ICIs. These include, but are 
not limited to, the distribution of the target immune checkpoint protein; the immune cell 
context within the tumour; the availability, immunogenicity and frequency of tumour antigens; 
the pharmacodynamics and pharmacokinetics of the ICI; and the amenability of the TME for 
effective drug delivery [160]. The analysis of these factors must be incorporated into the design 
of future clinical trials so that combinations of biomarkers that predict response to ICI 
immunotherapy can be identified and exploited. It will also be important to further clarify the 
reciprocal relationship between tumour cells and the TME in the context of ICI therapies, 
particularly if they are to be implemented across a range of different malignancies. Clinical trials 
have evolved from when tumours were classified according to histological observations, and 
comprehensive molecular, cellular and genetic phenotyping is now possible. Genomic and 
transcriptomic analysis of pre-treatment melanoma has identified a transcriptional signature 
associated with innate resistance to anti-PD1 therapy, and demonstrated that mutations in the 
DNA repair gene BRCA2 are enriched in patients that do respond [161]. The analysis of serial 
tumour biopsies taken before, during and after ICI therapy will further enhance understanding 
of how anti-tumour responses are induced by ICIs, and how tumours adapt to evade or limit 
these responses. Interestingly, one study has identified mutations in melanoma cells in patients 
whose disease progressed after initially responding to PD-1 blockade [162], and at least one trial 
is underway that aims to understand the selection pressures and evolutionary changes that ICIs 
impose on tumour cells [163].   
Concluding remarks. 
The development and application of ICIs has been a major advance in the treatment of cancer, 
dramatically rekindling academic, clinical and commercial interest in anti-cancer 
immunotherapies. As monotherapies, they show considerable promise and remarkable 
responses have been seen in some patients. However it is clear that there is improved efficacy 
when these ICIs are used as part of a concerted therapeutic approach for management of 
malignant disease. The key issue to be resolved is generation of sufficient evaluable data from 
combinatorial trials to define effective parameters for treatment. Results from current trials 
where ICIs are combined with chemotherapy, radiotherapy or with other immunotherapies are 
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starting to demonstrate which malignancies are particularly susceptible to immune reactivation. 
These studies are also providing clear evidence that though ICIs have produced dramatic 
improvements in some patients, they are not necessarily sufficient to mediate long-term 
remission or cure in most. Identification and validation of suitable prognostic markers in patient 
cohorts will also help to stratify treatment modalities and target therapy to those patients most 
likely to respond. The corollary to this is that suitable prognostic criteria could also minimize the 
IAEs associated with ICI treatment and immune reactivation [164]. The management of side 
effects and the evolution of resistance are ongoing concerns, but further advances are 
anticipated as these new medicines are incorporated into combination therapies and integrated 
into precision oncology. Progress is likely to be swift given the current explosion in clinical trials 
of ICIs and the rapidly expanding number of preclinical studies involving these drugs will no 
doubt stimulate further clinical applications. The range of new ICIs becoming available, and the 
novel checkpoint targets being identified and characterised in preclinical studies, means that the 
resistance or relapse seen in some patients could be reversed by using alternative checkpoint 
inhibitors. There is also a significant new approach to tumour immunotherapy with the recent 
FDA approval for autologous gene-modified chimeric antigen receptor (CAR) T cell therapy. This 
cell therapy (Kymriah, Novartis) targets CD19 in B cell acute lymphocytic leukaemia and has 
shown significant efficacy [165]. There are several other CAR-T cell therapies in development, 
and combination therapy with ICIs is already planned, offering the potential for even greater 
benefits. ICIs are important new weapons in the oncologist’s arsenal and exciting times lie 
ahead in the field of cancer immunotherapy.  
This article is protected by copyright. All rights reserved.
 17 
Acknowledgements. 
The authors would like to thank Alison Schroeer of Schroeer Scientific Illustration for assistance 
with the preparation of figure 2. 
Competing Interests 
The authors confirm that they have no competing financial interests or activities. 
 
References.  
1. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor 
microenvironment. Nat Immunol 2013: 14(10); 1014-22.  
2. Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev 
Immunol 2016: 16(10); 599-611.  
3. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and 
immunoediting. Immunity 2004: 21(2); 137-48.  
4. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 
2008: 27(28); 3889-900.  
5. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor 
counterattack. J Leukoc Biol 2002: 71(6); 907-920.  
6. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007: 117(5); 1137-46. 
7. Bouzin C, Brouet A, De Vriese J, Dewever J, Feron O. Effects of vascular endothelial growth 
factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric 
oxide as control points of endothelial cell anergy. J Immunol 2007: 178(3); 1505-11.  
8. Buckanovich RJ et al. Endothelin B receptor mediates the endothelial barrier to T cell 
homing to tumors and disables immune therapy. Nat Med 2008: 14(1); 28-36.  
9. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role 
of regulatory T cells in cancer progression. Clin Exp Immunol 2013: 171(1); 36-45. 
10. Facciabene A, Motz GT, Coukos G. T Regulatory Cells: Key Players in Tumor Immune 
Escape and Angiogenesis. Cancer Res 2012: 72(9); 2162-71.  
11. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell 2010: 140(6); 
883-99.  
This article is protected by copyright. All rights reserved.
 18 
12. Dong H et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism 
of immune evasion. Nat Med 2002: 8(8); 793-800.  
13. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev 
Immunol 2008: 8(6); 467-77.  
14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev 
Cancer 2012: 12(4); 252-64.  
15. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-
stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992: 
356(6370); 607-9. 
16. McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 co-stimulation in activation and 
differentiation of CD4+ and CD8+ T cells. Immunol Rev 1998: 165; 231-47. 
17. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR 
signalling. Nat Rev Immunol 2003: 3(12); 939-51. 
18. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev 
Immunol 2013: 13(4); 227-42. 
19. Krummel MF, Allison JP. CD28 and CTLA-4 Have Opposing Effects on the Response of T 
cells to Stimulation. J Exp Med 1995: 182; 459-465. 
20. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson 
CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. 
Immunity 1994: 1(5); 405-13. 
21. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev 
Immunol 2001: 1(3); 220-8. 
22. Lee KM et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998: 282(5397); 
2263-6. 
23. Schneider H et al. Reversal of the TCR stop signal by CTLA-4. Science 2006: 313(5795); 
1972-5.  
24. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell 
responses. Nat Rev Immunol 2011: 11(12); 852-63. 
25. Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W, Linsley PS. Covalent 
dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell 
costimulatory interactions. J Biol Chem 1996: 271(43); 26762-71.  
This article is protected by copyright. All rights reserved.
 19 
26. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological 
synapse is regulated by TCR signal strength. Immunity 2002: 16(1); 23-35. 
27. Yokosuka T et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated 
negative regulation of T cell activation. Immunity 2010: 33(3); 326-39. 
28. Qureshi OS et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-
extrinsic function of CTLA-4. Science 2011: 332(6029); 600-3.  
29. Walker LS, Sansom DM. Confusing signals: Recent progress in CTLA-4 biology. Trends 
Immunol 2015: 36(2); 63-70. 
30. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 
leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a 
critical negative regulatory role of CTLA-4. Immunity 1995: 3(5); 541-7. 
31. Waterhouse P et al. Lymphoproliferative disorders with early lethality in mice deficient in 
Ctla-4. Science 1995: 270(5238); 985-8. 
32. Kuehn HS et al. Immune dysregulation in human subjects with heterozygous germline 
mutations in CTLA4. Science 2014: 345(6204); 1623-7.  
33. Schubert D et al. Autosomal dominant immune dysregulation syndrome in humans with 
CTLA4 mutations. Nat Med 2014: 20(12); 1410-6.  
34. Zeissig S et al. Early-onset Crohn's disease and autoimmunity associated with a variant in 
CTLA-4. Gut 2015: 64(12); 1889-97. 
35. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-
4 blockade. Science 1996: 271(5256); 1734-6. 
36. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. 
Combination immunotherapy of primary prostate cancer in a transgenic mouse model 
using CTLA-4 blockade. Cancer Res 2000: 60(9); 2444-8. 
37. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-
CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of 
intratumoral regulatory T cells. Cancer Immunol Res 2013: 1(1); 32-42. 
38. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination 
immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin 
Invest 2006: 116(7); 1935-45. 
39. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both 
effector and regulatory T cell compartments contributes to the antitumor activity of anti-
CTLA-4 antibodies. J Exp Med 2009: 206(8); 1717-25.  
This article is protected by copyright. All rights reserved.
 20 
40. Simpson TR et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-
defines the efficacy of anti-CTLA-4 therapy against melanoma.  J Exp Med 2013: 210(9); 
1695-710.  
41. Bulliard Y et al. Activating Fc γ receptors contribute to the antitumor activities of 
immunoregulatory receptor-targeting antibodies. J Exp Med 2013: 210(9); 1685-93.  
42. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement 
depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. Immunol 
Cell Biol 2014: 92(6); 475-80. 
43. Śledzińska A, Menger L, Bergerhoff K, Peggs KS, Quezada SA. Negative immune 
checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol 
2015: 9(10); 1936-65.  
44. Romano E et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex 
vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci 2015: 112(19); 
6140-5.  
45. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of 
the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992: 11(11); 
3887-95.  
46. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the 
PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996: 
8(5); 765-72.  
47. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. 
Annu Rev Immunol 2008: 26; 677-704.  
48. Yamazaki T, Akiba H, Iwai H et al. Expression of programmed death 1  ligands by murine T 
cells and APC. J Immunol 2002: 169(10); 5538-45.  
49. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, Leonard JP. 
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular 
endothelial cells. Microcirculation 2002: 9(2); 133-45. 
50. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013: 
2(5); 662-673. 
51. Latchman Y et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature 
Immunol 2001: 2(3); 261–268. 
This article is protected by copyright. All rights reserved.
 21 
52. Freeman GJ et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family 
member leads to negative regulation of lymphocyte activation. J Exp Med 2000: 192(7); 
1027–34. 
53. Hui E et al. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated 
inhibition Science 2017: 355(6332); 1428-33. 
54. Fife BT et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-
induced stop signal. Nat Immunol 2009: 10(11); 1185-92. 
55. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 
interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. 
Immunity 2007: 27(1); 111-22. 
56. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune 
diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. 
Immunity 1999: 11(2); 141-51. 
57. Nishimura H et al. Autoimmune dilated cardiomyopathy in PD-1 receptor deficient 
mice. Science 2001: 291(5502); 319–322. 
58. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. Viral 
immune evasion due to persistence of activated T cells without effector function. J Exp 
Med 1998: 188(12); 2205-13.  
59. Gallimore A, Glithero A, Godkin A, Tissot AC, Plückthun A, Elliott T, Hengartner 
H, Zinkernagel R. Induction and exhaustion of lymphocytic choriomeningitis virus-specific 
cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility 
complex class I-peptide complexes. J Exp Med 1998: 187(9); 1383-93. 
60. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006: 
439(7077); 682-7.  
61. Kamphorst OA et al Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-
dependent Science 2017: 355(6332); 1423-27. 
62. Thompson RH et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of 
tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004: 
101(49); 17174-9. 
63. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is 
expressed by tumor-infiltrating immune cells and is associated with poor outcome for 
patients with renal cell carcinoma. Clin Cancer Res 2007: 13(6); 1757-61. 
This article is protected by copyright. All rights reserved.
 22 
64. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White 
DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high 
levels of PD-1 and are functionally impaired. Blood 2009: 114(8); 1537-44. 
65. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated 
with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung 
cancer. Cell Mol Immunol 2010: 7(5); 289-95. 
66. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. Tumor 
cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant 
melanoma. Cancer 2010: 116(7); 1757-66. 
67. Shi F et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and 
postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011: 128(4); 
887-96.  
68. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor 
cells in the escape from host immune system and tumor immunotherapy by PD-L1 
blockade. Proc Natl Acad Sci USA 2002: 99(19); 12293-7.  
69. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 
inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T 
cells. Cancer Res 2004: 63(3); 1140-5. 
70. Strome SE et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous 
cell carcinoma. Cancer Res 2003: 63(19); 6501-5. 
71. Hirano F et al. Blockade of B7–H1 and PD-1 by monoclonal antibodies potentiates cancer 
therapeutic immunity. Cancer Res 2005: 65(3); 1089-96. 
72. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in 
peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease 
progression through PD-L1. J Exp Med 2009: 206(6); 1327-37.  
73. Curiel TJ et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor 
immunity. Nat Med 2003: 9(5); 562-7.  
74. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-
L1 regulates the development, maintenance, and function of induced regulatory T cells. J 
Exp Med 2009: 206(13); 3015-29.  
75. FDA.gov. 2011 Notifications. 
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381453.htm 
(Accessed: 13/10/2017). 
This article is protected by copyright. All rights reserved.
 23 
76. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N 
Engl J Med 2010: 363(8); 711-23. 
77. Rosenberg SA et al. Immunologic and therapeutic evaluation of a synthetic peptide 
vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998: 4(3); 321-
7.  
78. Smith FO et al. Treatment of metastatic melanoma using interleukin-2 alone or in 
conjunction with vaccines. Clin Cancer Res 2008: 14(17); 5610-18.  
79. Weber J et al. A randomized, double-blind, placebo-controlled, phase II study comparing 
the tolerability and efficacy of ipilimumab administered with or without prophylactic 
budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009: 
15(17); 5591-8.  
80. Wolchok JD et al. Ipilimumab monotherapy in patients with pretreated advanced 
melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet 
Oncol 2010: 11(2); 155-64.  
81. O'Day SJ et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated 
advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010: 21(8); 
1712-7.  
82. Schadendorf D et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase 
III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015: 33(17); 
1889-94.  
83. Robert C et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in 
ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a 
phase 1 trial. Lancet 2014: 384(9948); 1109-17. 
84. Eisenhauer EA et al. New response evaluation criteria in solid tumours: revised RECIST 
guideline (version 1.1). Eur J Cancer 2009: 45(2); 228-47. 
85. FDA.gov. Hematology/Oncology (Cancer) Approvals & Safety Notifications. 
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm 
(Accessed: 13/10/2017). 
86. Robert C et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 
2015: 372(26); 2521-32. 
87. Schachter J et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall 
survival analysis of KEYNOTE-006. J Clin Oncol 2016: 34; (suppl; abstr 9504). 
This article is protected by copyright. All rights reserved.
 24 
88. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. 
N Engl J Med 2012: 366(26); 2443-54. 
89. Topalian SL et al. Survival, durable tumor remission, and long-term safety in patients with 
advanced melanoma receiving nivolumab. J Clin Oncol 2014: 32(10); 1020-30.  
90. Weber JS et al. A phase 3 randomized, open-label study of nivolumab (anti–PD-1; BMS-
936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with 
advanced melanoma with prior anti-CTLA-4 therapy. European Society for Medical 
Oncology 2014 Congress 2014. 
91. Robert C et al. Nivolumab in previously untreated melanoma without BRAF mutation. N 
Engl J Med 2015: 372(4); 320-30.  
92. Wolchok JD et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013: 
369(2); 122-33. 
93. Sznol M et al. Survival, response duration, and activity by BRAF mutation (MT) status of 
nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent 
therapy in advanced melanoma (MEL). J Clin Oncol 2014: 32; Suppl:9003-9003. 
94. Postow MA et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N 
Engl J Med 2015: 372(21); 2006-17.  
95. Hodi FS et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients 
with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, 
controlled, phase 2 trial. Lancet Oncol 2016: 17(11); 1558-68.  
96. Larkin J et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated 
Melanoma. N Engl J Med 2015: 373(1); 23-43.  
97. Wolchok JD et al. Overall survival with combined nivolumab and ipilimumab in advanced 
melanoma. New Engl J Med 2017: 377(14); 1345-56.  
98. Weber JS et al. Sequential administration of nivolumab and ipilimumab with a planned 
switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, 
phase 2 trial. Lancet Oncol 2016: 17(7); 943-55.  
99. Zatloukal P et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) 
with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) 
with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009: 27:abstr 8071. 
100. Lynch TJ et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line 
treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-
blind, multicenter phase II study. J Clin Oncol 2012: 30(17); 2046-2054. 
This article is protected by copyright. All rights reserved.
 25 
101. Govindan R et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in 
Advanced Squamous Non-Small-Cell Lung Cancer. J Clin Oncol 2017: 35(30); 3449-57. 
102. Brahmer J et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell 
Lung Cancer. N Engl J Med 2015: 373(2); 123-35.  
103. Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell 
Lung Cancer. N Engl J Med 2015: 373(17); 1627-39. 
104. Rizvi NA et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, 
for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 
063): a phase 2, single-arm trial. Lancet Oncol 2015: 16(3); 257-65.  
105. Herbst RS et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, 
advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 
2016: 387(10027); 1540-50.  
106. Herbst RS et al. Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-
L1–expressing NSCLC: Updated outcomes of KEYNOTE-010. Ann Oncol 2016: 27(suppl 6). 
107. Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J 
Med 2015: 372(21); 2018-28.  
108. Reck M et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung 
Cancer. N Engl J Med 2016: 375(19); 1823-33. 
109. Carbone DP, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. 
New Engl J Med 2017: 376(25); 2415-2426. 
110. Fehrenbacher L et al. Atezolizumab versus docetaxel for patients with previously treated 
non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised 
controlled trial. Lancet 2016: 387(10030); 1837-46.  
111. Rittmeyer A et al. Atezolizumab versus docetaxel in patients with previously treated non-
small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled 
trial. Lancet 2017: 389(10066); 255-65.  
112. Barles F et al. Primary analysis from OAK, a randomized phase III study comparing 
atezolizumab with docetaxel in 2L/3L NSCLC. Ann Oncol 2016: 27(Supplement 6); vi552-
vi587. 
113. Remon J et al. Immune-checkpoint inhibition in first-line treatment of advanced non-small 
cell lung cancer patients: Current status and future approaches. Lung Cancer 2017: 106; 
70-75. 
114. Antonia S et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-
This article is protected by copyright. All rights reserved.
 26 
small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016: 17(3); 299-308.  
115. Hellmann MD et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-
small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort 
study. Lancet Oncol 2017: 18(1); 31-41. 
116. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in 
Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of 
Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC). 
ClinicalTrials.gov. https://clinicaltrials.gov/show/NCT02352948 (Accessed: 13/10/2017). 
117. Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without 
Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC). 
ClinicalTrials.gov. https://clinicaltrials.gov/show/NCT02453282 (Accessed: 13/10/2017).  
118. Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non 
Small-Cell Lung Cancer (NSCLC) (NEPTUNE). (NEPTUNE). ClinicalTrials.gov. 
https://clinicaltrials.gov/show/NCT02542293 (Accessed: 13/10/2017).  
119. Antonia SJ, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung 
cancer. New Engl J Med 2017: doi:10.1056/NEJMoa1709937.  
120. Thompson RH et al Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of 
tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci 2004: 101(49); 
17174-9.  
121. Thompson RH et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma 
patients with long-term follow-up. Cancer Res 2006: 66(7); 3381-5.  
122. Motzer RJ et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized 
Phase II Trial. J Clin Oncol 2015: 33(13); 1430-7.  
123. Motzer RJ et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J 
Med 2015: 373(19); 1803-13.  
124. Rosenberg JE et al. Atezolizumab in patients with locally advanced and metastatic 
urothelial carcinoma who have progressed following treatment with platinum-based 
chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016: 387(10031); 1909-20. 
125. Sharma P et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma 
(CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet 
Oncol 2016: 17(11); 1590-98.  
126. Snyder A et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl 
J Med 2014: 371(23); 2189-99.  
This article is protected by copyright. All rights reserved.
 27 
127. Hugo W et al. Genomic and Transcriptomic Response to Anti-PD-1 Therapy in Metastatic 
Melanoma. Cell 2016: 165(1); 35-44.  
128. Le DT et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015: 
372(26); 2509-20.  
129. Domchek S, et al. MEDIOLA: A phase I/II, open-label trial of olaparib in combination with 
durvalumab (MEDI4736) in patients with advanced solid tumours. Ann Oncol 2016: suppl 6; 
1103TiP  
130. Ansell SM et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s 
Lymphoma. N Engl J Med 2015: 374(4); 311-19.  
131. Armand P et al. Programmed Death-1 Blockade with Pembrolizumab in Patients with 
Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 2016: 34(31); 
373-39.  
132. Chow LQ et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients 
With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From 
the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol 2016: 34(32); 3838-45. 
133. Ferris RL et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. 
N Engl J Med 2016: 375(19); 1856-67.  
134. Cohen EE, et al. Pembrolizumab versus standard of care for recurrent or metastatic head 
and neck squamous cell carcinoma: Phase 3 KEYNOTE-040 trial. Ann Oncol 2017: 28 (suppl 
5) 628, LBA45.  
135. Kaufman HL et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel 
cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016: 
17(10); 1374-85.  
136. Liu W, MacDonald M, You J. Merkel cell polyomavirus infection and Merkel cell carcinoma. 
Curr Opin Virol 2016: 20; 20-27.  
137. Nghiem PT et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. 
N Engl J Med 2016: 374(26); 2542-52.  
138. Reck M et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus 
Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin 
Oncol 2016: 34(31); 3740-48.  
139. Reck M et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line 
therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-
blind, multicenter phase 2 trial. Ann Oncol 2013: 24(1); 75-83.  
This article is protected by copyright. All rights reserved.
 28 
140. Antonia SJ et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell 
lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 
2016: 17(7); 883-95 
141. Ott PA et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell 
lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol 
2015: 33; (suppl; abstr 7502). 
142. Kwon ED et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic 
castration-resistant prostate cancer that had progressed after docetaxel chemotherapy 
(CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014: 
15(7); 700-12.  
143. Wolchok JD et al. Guidelines for the evaluation of immune therapy activity in solid tumors: 
immune-related response criteria. Clin Cancer Res 2009: 15(23); 7412-20.  
144. Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer. ClinicalTrials.gov. 
https://clinicaltrials.gov/ct2/show/NCT01057810 (Accessed 14/04/2017). 
145. Muro K et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer 
(KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016: 17(6); 717-
26.  
146. Le DT et al. Safety and activity of nivolumab monotherapy in advanced and metastatic 
(A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-
032 study. J Clin Oncol 2016: 34; (suppl4S; abstr 6).  
147. El-Khoueiry AB et al. Phase I/II safety and antitumour activity of nivolumab in patients with 





149. Twyman-Saint Victor C et al. Radiation and dual checkpoint blockade activate non-
redundant immune mechanisms in cancer. Nature 2015: 520(7547); 373-7.  
150. Postow MA et al. Immunologic correlates of the abscopal effect in a patient with 
melanoma. N Engl J Med 2012: 366(10); 925-31.  
151. Schoenfeld JD et al. Ipilmumab and cranial radiation in metastatic melanoma patients: a 
case series and review. J Immunother Cancer 2015: 3:50. 
This article is protected by copyright. All rights reserved.
 29 
152. Simone CB, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: 
combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res 
2015: 4(5); 545-52.  
153. Palma DA, Louie AV, Rodrigues GB. New Strategies in Stereotactic Radiotherapy for 
Oligometastases. Clin Cancer Res 2015: 21(23); 5198-204.  
154. Okwan-Duodu D1, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune 
activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J 
Clin Oncol 2015: 38(1); 119-25.  
155. Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic 
Cancer Patients (CheckPAC). ClinicalTrials.gov. 
https://clinicaltrials.gov/ct2/show/NCT02866383?term=pancreas+AND+ipilimumab&rank
=5. (Accessed: 13/10/2017).  




157. Peng D et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and 
immunotherapy. Nature 2015: 527(7577); 249-53.  
158. Steele CW et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments 
Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell 2016: 29(6); 832-45. 
159. Vargas et al. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and 
Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity. 2017: 46(4); 
577-586. 
160. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015: 348 (6230); 
56-61. 
161. Hugo W et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in 
Metastatic Melanoma. Cell 2016: 165(1); 35-44.  
162. Zaretsky JM et al. Mutations Associated with Acquired Resistance to PD-1 Blockade 
in Melanoma. N Engl J Med 2016: 375(9); 819-29. 
163. Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other 
Immunologic Therapies (SPECIAL). ClinicalTrials.gov. 
https://clinicaltrials.gov/ct2/show/NCT02724488?term=checkpoint+inhibitors&rank=1. 
(Accessed: 20/08/2016). 
This article is protected by copyright. All rights reserved.
 30 
164. Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker 
research for PD-1/PD-L1 immune checkpoint blockade therapy J Hematol Oncol 2016: 9;47 
165. Khalil D, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: 
immunomodulation, CARs and combination immunotherapy. Nature Rev Clin Oncol 2016: 
13; 273–90. 
This article is protected by copyright. All rights reserved.
 31 
Figure 1: History of Checkpoint Inhibitors: Key Milestones 
Timeline showing when checkpoint inhibitors were approved for the treatment of specific 
cancers in the USA, Europe and Japan.  Tumour type is indicated by the colour of each ICI 
depicted in the figure, according to the key in the top left. 
Abbreviations: 1L, first line; 2L, second line; NSCLC, non-small cell lung cancer; NSQ, 
nonsquamous; PD-L1, programmed death ligand 1; RCC, renal cell carcinoma; R/M, 
recurrent/metastatic; SCCHN, squamous cell carcinoma of the head and neck; SQ, squamous.  
1 U.S. Food and Drug Administration. http://www.fda.gov. Accessed November 11, 2016. 2 
European Medicines Agency. http://www.ema.europa.eu. Accessed November 11, 2016. 3 ONO 
Pharmaceutical Co., Ltd. [press release] July 4, 2014. 4 ONO Pharmaceutical Co, Ltd. [press 
release]. March 23, 2015. 5 ONO Pharmaceutical Co, Ltd. [press release]. December 17, 2015. 6 
Merck [press release]. June 27, 2016. Accessed August 8, 2016. 7 Bristol-Myers Squibb Company 
[press release]. November 22, 2016. 8. Merck [press release]. December 19, 2016. 
 
Figure 2: ICI blockade reverses tumour-mediated immune suppression 
A) Established tumours block immune attack through a variety of mechanisms including 
inhibition of tumour-specific CTL and CD4 T cell activation and function (1). This is driven by 
tumour over-expression of PD-L1, interacting with tumour-specific T cell PD-1 receptor (2) and T 
cell anergy induced by tumour-mediated T cell expression of CTLA-4 inhibitory receptor (4). In 
addition, tolerogenic DC drive Treg induction and expansion via CTLA-4 (3) and accumulation of 
Tregs then contributes to the immunosuppressive milieu of the TME. 
B) After ICI therapy, there is re-activation and proliferation of tumour-specific CTLs via blockade 
of PD-1 axis (1), and return of functional cytotoxicity, resulting in perforin release and tumour 
cell killing (2). As tumour damage increases, the TME is disrupted allowing macrophages to 
deplete Tregs via FcR binding of anti-CTLA-4 antibody (3). Tumour antigen release is driven by 
immune lysis of tumour cells which are processed by conventional DC and presented to naive T 
cells in context of checkpoint inhibition of CTLA-4, enhancing CTL proliferation and function (4). 
Tumour damage and antigen release is also supplemented by concomitant use of conventional 
chemo/radiotherapy, which can reveal new tumour-associated antigens and contribute to anti-
tumour immune responses (5). 













2-Year OS Rate 
(%) 
Median OS (Months) 
Phase III [76] Ipi (3mg/kg) vs gp100 vaccine 676 45.6 vs 25.3 33.2 vs 16.3 23.5 vs 13.7 10.1 vs 6.4 
Phase II [79] Ipi (10mg/kg) + Budesonide vs Ipi (10mg/kg)  115 55.9 vs 62.4  N/R 40.5 vs 41.7 17.7 vs 19.3  
Phase II [80] Ipi (10 vs 3 vs 0.3mg/kg) 217 48.6 vs 39.3 vs 
39.6  
34.5 vs 30.2 vs 
23.0 
29.8 vs 24.2 vs 
18.4 
11.4 vs 8.7 vs 8.6  
Phase II [81] Ipi (10mg/kg) 226 47.2 39.4 32.8 10.2 
KEYNOTE-006 
Phase III [86, 87]  
Pembro (10mg/kg every 2 weeks) vs Pembro 
(10mg/kg every 3 weeks) vs   Ipi (3mg/kg 
every 3 weeks) 
834 74.1 vs 68.4 vs 
58.2 
N/R 55.1 vs 55.3 vs 
43.0 
N/A vs N/A vs 16.0 
Phase I [88, 89] Pembro (1-10mg/kg) 104 62 N/R 43 16.8 
Phase III [91] Niv (3mg/kg) vs Dacarbazine (1000mg/m
2) 418 72.9 vs 42.1 N/A N/A N/A vs 10.8 
Phase I [92, 93] Cohort 1: Niv (0.3mg/kg) +Ipi (3mg/kg) 14 56 N/A N/A 14.8 
Cohort 2: Niv (1mg/kg) + Ipi (3mg/kg) 17 94 N/A N/A N/R 
Cohort 2a: Niv (3mg/kg) +Ipi (1mg/kg) 16 89 N/A N/A N/R 
Cohort 3: Niv (3mg/kg) + Ipi (3mg/kg) 6 100 N/A N/A  N/R 
CHECKMATE 069 
Phase II [94, 95] 
Niv (1mg/kg) + Ipi (3mg/kg) vs Ipi (3mg/kg) 142 73.4 vs 64.8 
 





Phase III [96, 97] 
Niv (3mg/kg)  316 N/A N/A 59 37.6 
Niv (1mg/kg) + Ipi (3mg/kg), then Niv 
(3mg/kg) maintenance 
314 N/A N/A 64 N/A 
Ipi (3mg/kg) 315 N/A N/A 45 19.9 
CHECKMATE 064  
Phase II [98] 
Niv (3mg/kg), then Ipi (3mg/kg) 68 76 N/A N/A N/A 
Ipi (3mg/kg), then Niv (3mg/kg) 70 54 N/A N/A 16.9 
 
Table 1: Key clinical trials of ICIs in patients with malignant melanoma, and their associated survival data. Ipi, ipilimumab; Pembro, 
pembrolizumab; Niv, nivolumab; OS, overall survival; N/A, not available; N/R, not reported. 
 
 





























Phase III [104] 
Sq NSCLC Niv (3mg/kg) 117 40.8 8.2 14.5 1.9 Yes 17 
CHECKMATE-
017 
Phase III [102] 
Sq NSCLC Niv (3mg/kg) vs 
Docetaxel  
272 42 vs 24 9.2 vs 6.0 20 vs 9  
 
3.5 vs 2.8 N/R 7 vs 55 
CHECKMATE-
057 
Phase III [103] 
Non-Sq 
NSCLC 
Niv (3mg/kg) vs 
Docetaxel 
582 51 vs 39 12.2 vs 
9.4 
19 vs 12  
 
2.3 vs 4.2 Yes 10 vs 54 
KEYNOTE-001 
Phase I [107] 
NSCLC Pembro  
(2-10mg/kg) 
495 N/R 12.0 19.4 3.7 Yes 9.5 
KEYNOTE-010 
















N/R 3.9 vs 4.0 
vs 4.9 
 
Yes 13 vs 16 vs 35 
KEYNOTE-024 






305 N/R N/R 44.8 vs 27.8 10.3 vs 
6.0 
 
High PD-L1 a 
prerequisite for 
inclusion in trial 
26.6 vs 53.3 
POPLAR 
Phase II [109] 
NSCLC 
 
Atezo (1200mg) vs 
Docetaxel  




15 vs 15 2.7 vs 3.0 
 
Yes 40 vs 53 
OAK Phase III 
[110, 111] 
NSCLC Atezo vs Docetaxel 1225 55 vs 41 13.8 vs 
9.6 
14 vs 13 2.8 vs 4.0 Yes 37 vs 54 
Phase 1b [112] NSCLC Durvalumab + 
Tremelimumab 
102 N/R N/R 0-23 N/R N/R 36 
CHECKMATE-
012 
Phase 1 [115] 
NSCLC Niv (3mg/kg) + Ipi 





N/R 47 vs 38 8.1 vs 3.9 Yes 37 vs 33 
 
Table 2: Key trials of ICIs targeting the PD-1 pathway in patients with non-small-cell lung cancer (NSCLC). Sq, Squamous; Non-Sq, non-
squamous; Niv, nivolumab; Pembro, pembrolizumab; Atezo, atezolizumab; Ipi, ipilumumab; OS, overall survival; PFS, progression-free survival; 
N/R, not reported.  
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